Purnell, Jonathan Q.
Johnson, Geoffrey S.
Wahed, Abdus S.
Dalla Man, Chiara
Piccinini, Francesca
Cobelli, Claudio
Prigeon, Ronald L.
Goodpaster, Bret H.
Kelley, David E.
Staten, Myrlene A.
Foster-Schubert, Karen E.
Cummings, David E.
Flum, David R.
Courcoulas, Anita P.
Havel, Peter J.
Wolfe, Bruce M.
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (DK103842; DK066557; DK66667; DK66568;DK66471; DK66)
Article History
Received: 12 June 2017
Accepted: 22 November 2017
First Online: 10 February 2018
Duality of interest
: JQP receives consultant income for services on an advisory board for Novo Nordisk and receives grant funding from the NIH. CC holds ten patents and patent applications related to glucose sensors and artificial pancreas, received non-financial support from Roche and Dexcom, Inc., research support from Dexcom, Inc., Sanofi Aventis and Adocia and consultant income for services on an advisory board for Novo Nordisk. From 2007–2017, DEK was a full-time employee of Merck & Co. Inc., receiving salary and stock, but is now retired. DEC receives research support from Johnson & Johnson, the NIH and Medtronic. DRF receives consulting fees from Pacira Pharm and Patient Centered outcomes with Surgical Consulting LLC. APC receives grant support from the NIH and Covidien/Ethicon J&J. All other authors declare that there is no duality of interest associated with their contribution to this manuscript.
Free to read: This content has been made available to all.